Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Operations (2021 - 2025)

InMed Pharmaceuticals' Cash from Operations history spans 5 years, with the latest figure at 2376243.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 5.03% year-over-year to 2376243.0; the TTM value through Dec 2025 reached 7421862.0, down 1.77%, while the annual FY2025 figure was 7766951.0, 11.18% down from the prior year.
  • Cash from Operations reached 2376243.0 in Q4 2025 per INM's latest filing, down from 1607616.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 657934.0 in Q2 2023 to a low of 5348786.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 2311311.06, with a median of 2054267.5 recorded in 2023.
  • Peak YoY movement for Cash from Operations: soared 83.74% in 2023, then plummeted 72.81% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 3533808.0 in 2021, then increased by 23.22% to 2713096.0 in 2022, then soared by 31.88% to 1848133.0 in 2023, then tumbled by 35.39% to 2502138.0 in 2024, then increased by 5.03% to 2376243.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Cash from Operations are 2376243.0 (Q4 2025), 1607616.0 (Q3 2025), and 1778506.0 (Q2 2025).